Market revenue in 2023 | USD 5,775.7 million |
Market revenue in 2030 | USD 22,373.3 million |
Growth rate | 21.3% (CAGR from 2023 to 2030) |
Largest segment | Instruments |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Consumables, Instruments, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Agilent Technologies Inc, Illumina Inc, Qiagen NV, Roche Holding AG, Macrogenics Inc, PerkinElmer, Pacific Biosciences of California Inc, BGI Group, BGC Group Inc Ordinary Shares Class A, Bio-Rad Laboratories Inc, Myriad Genetics Inc, PierianDx, Eurofins Scientific SE |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dna sequencing market will help companies and investors design strategic landscapes.
Instruments was the largest segment with a revenue share of 48.95% in 2023. Horizon Databook has segmented the U.S. dna sequencing market based on consumables, instruments, services covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. dominated North America’s market due to its extensive genomics, oncology, and whole genome sequencing research. Other factors that can be attributed to the significant adoption of DNA sequencing technology in this country are sophisticated research & medical infrastructure, funding, skilled personnel, and companies pushing for better research methods to identify newer technologies.
The U.S. is witnessing rapid clinical developments in NGS methodologies for applications in oncology and infectious diseases. Presence of market leaders, such as Illumina, Roche, and Life Technologies, which are involved in the development of rapid and high-throughput sequencing capabilities, has contributed to the country’s market growth.
These players are undertaking several strategic initiatives to strengthen their market presence in the country. For instance, in February 2022, Agilent Technologies, Inc. partnered with Element Biosciences, Inc. to integrate the latter’s AVITI System with Agilent’s Sure Select target enrichment panels for enhancing customer access to genomic tools.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. dna sequencing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. dna sequencing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account